Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.89 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.89 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myosmine SCHEMBL29398376 | 1.00 | ALDH1A1 (1.00) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 | |
| Anabaseine SCHEMBL30394330 | 0.94 | CHRNB4 (1.00) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 | |
| Anabaseine SCHEMBL261062 | 0.94 | CHRNB4 (1.00) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 | |
| SCHEMBL6807730 | 0.93 | CHRNB4 (0.96) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 | |
| SCHEMBL6807223 | 0.93 | CHRNB4 (0.96) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 | |
| SCHEMBL6807728 | 0.93 | CHRNB4 (0.96) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 | |
| SCHEMBL165812 | 0.77 | CHRNB4 (0.87) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 | |
| SCHEMBL3161806 | 0.77 | — | — | |
| SCHEMBL24344048 | 0.75 | CHRNA7 (0.68) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 | |
| SCHEMBL13114823 | 0.75 | ALDH1A1 (0.60) | ALDH1A1CYP1A2THRBCYP2C19CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115669977-B | Preparation method of cigar-flavored pipe tobacco shreds | 河南中烟工业有限责任公司 | 2024-06-18 | — | — | CN | claimed |
| WO-2023195790-A1 | METHOD FOR MANUFACTURING BIOMATERIAL FOR TISSUE REPAIR WITH EXCELLENT SAFETY | ㈜아크로스 | 2023-10-12 | — | — | WO | claimed |
| CN-116326809-A | Preparation method of cigar-flavored chewing tobacco | 河南中烟工业有限责任公司 | 2023-06-27 | — | — | CN | claimed |
| CN-116286700-A | Imine reductase mutant and application thereof | 迪嘉药业集团股份有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-115669977-A | Preparation method of cigar-flavor pipe tobacco shreds | 河南中烟工业有限责任公司 | 2023-02-03 | — | — | CN | claimed |
| CN-113774036-B | Imine reductase mutant and application thereof | 迪嘉药业集团有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-113774036-A | Imine reductase mutant and application thereof | 迪嘉药业集团有限公司 | 2021-12-10 | — | — | CN | claimed |
| CN-112125883-A | Synthesis method of racemic nicotine | 东莞市鸿馥生物科技有限公司 | 2020-12-25 | — | — | CN | claimed |
| EP-4580622-A2 | ANTI-INFLAMMATORY COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING HEMOCHROMATOSIS, AND OTHER DISORDERS | Miralogx LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-120152714-A | Anti-inflammatory compounds, pharmaceutical compositions, and methods of treating hemochromatosis and other diseases | 米拉洛克斯有限责任公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-3807260-B1 | PURIFICATION OF NICOTINE | REYNOLDS TOBACCO CO R (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-115669977-B | Preparation method of cigar-flavored pipe tobacco shreds | 河南中烟工业有限责任公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-115340524-B | Method for preparing (S) -nicotine by methylation of (S) -nornicotine | 重庆博腾制药科技股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024050374-A9 | ANTI-INFLAMMATORY COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING HEMOCHROMATOSIS, AND OTHER DISORDERS | MIRALOGX LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2008151073-A1 | COMPOUNDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AMYLOID ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-08-07 | — | — | US | disclosed |
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-08-07 | — | — | US | disclosed |
| CN-101139563-A | Novel bacterial strain for nicotine degradation-Pseudomonas ZUTSKD and uses thereof | UNIV ZHEJIANG TECHNOLOGY (CN) | 2008-03-12 | — | — | CN | disclosed |
| CN-101139563-A | Novel bacterial strain for nicotine degradation-Pseudomonas ZUTSKD and uses thereof | UNIV ZHEJIANG TECHNOLOGY (CN) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007093796-A2 | TOBACCO EXTRACTION METHODS AND FORMULATIONS | COTREX LLC (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | CYP2A13, CYP2A6, CYP2B6 | ALDH1A1 762/4885CYP1A2 19/4885THRB 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.